Aim: To assess the correlation between response to tolvaptan and treatment-related factors in liver cirrhosis patients.
INTRODUCTION
A SCITES IS THE MOST common complication of liver cirrhosis, and is due to cirrhosis-induced portal hypertension leading to splanchnic vasodilatation. 1, 2 In advanced cirrhosis, splanchnic arterial vasodilatation results in a decrease in effective arterial blood volume and the activation of potent vasoconstriction systems, such as the renin-angiotensin-aldosterone system (RAAS), sympathetic nervous system, and vasopressin release. [3] [4] [5] Tolvaptan is an oral, non-peptide, selective vasopressin V 2 receptor antagonist that blocks arginine vasopressin from binding to V 2 receptors in the distal nephron. 6, 7 In contrast to furosemide, tolvaptan results in urine output without decreasing renal blood flow, and it seems to not activate the sympathetic nervous system or the RAAS, as it induces the excretion of electrolyte-free water without changing the total level of electrolyte excretion. [8] [9] [10] Recently, several studies have evaluated the effects of low doses of tolvaptan for treating liver cirrhosis patients. [11] [12] [13] Assuming a more prominent role in decompensated liver cirrhosis, the response to this drug is unpredictable. Therefore, the aim of this study was to assess the correlation between the efficacy of tolvaptan and treatment-related factors in liver cirrhosis patients.
METHODS

Patients
A SINGLE-CENTER RETROSPECTIVE studywas carried out at Shonan Kamakura General Hospital in Kanagawa, Japan, between October 2013 and September 2015. According to a phase III, multicenter, randomized, double-blind, placebo-controlled trial, 12 this study enrolled 43 decompensated liver cirrhosis patients without improvement of body weight and ascites, even after undergoing standard combination therapy with a loop diuretic and an anti-aldosterone agent for at least 7 days. 14 For patients who required significant control of ascites after treatment with standard diuretic therapy, therapeutic abdominal paracentesis was carried out; however, the dose of diuretic medication was not changed for at least 7 days before tolvaptan treatment commenced. Patients with hepatic encephalopathy (coma scale ≥II) or poorly controlled hepatocellular carcinoma were excluded. Diagnosis of liver cirrhosis was based on laboratory results and imaging tests (ultrasonography and computed tomography) revealing a hepatic cirrhotic appearance, splenomegaly, esophageal varices, and ascites. 15 The study was approved by the Institutional Review Board Ethics Committee of the Tokushukai Medical Group.
Study protocols
All 43 patients received oral tolvaptan (7.5 mg/day for 7 days) in addition to the guideline-directed medical therapy, which included sodium intake restrictions (<6 g/day) and standard diuretic therapy, unless the subject was intolerant of diuretics.
14 This study consisted of a 2-day pretreatment observation period followed by a 7-day treatment period. The dose of conventional diuretics used prior to enrolment in this study was not changed, and therapeutic abdominal paracentesis was not carried out, until the completion of the final assessment on the day following the final treatment with tolvaptan. Patients were admitted to the hospital, and fluid intake was not restricted. Mean differences between daily urine volume and body weight were calculated. Cumulative 24-h urine samples were collected after patients had urinated completely before drug administration each day from the day before initiating tolvaptan until the end of the post-treatment period. Tolvaptan was given in the morning, and laboratory and urinary data were obtained at 6.00 AM before administration and after administration on day 7.
Clinical parameters
The baseline clinical characteristics included age, body weight, body mass index, Child-Pugh score, concomitant diuretic medication, 24-h urine volume, and laboratory and urinary data just before starting tolvaptan. The posttreatment characteristics included the mean 24-h urine volume after drug administration for 1 week and laboratory and urinary data after drug administration on day 7. Laboratory tests included levels of hemoglobin, platelets, serum albumin, serum blood urea nitrogen (BUN), serum creatinine, serum total bilirubin, serum sodium, serum potassium, serum osmolality (OSM), plasma brain natriuretic peptide (BNP), serum aldosterone, serum renin, and plasma arginine vasopressin (AVP). Urinary tests included OSM, sodium, and potassium. The 24-h creatinine clearance (24-h Ccr) was calculated by the following method: (urinary creatinine × urinary volume/serum creatinine) × 1440. 16 
Evaluation of treatment response
A responder to tolvaptan was defined as a patient having a ≥2-kg decrease in body weight by 1 week after commencement of drug treatment, and a nonresponder was a patient not losing ≥2 kg in body weight by 1 week after commencement of drug treatment. We investigated the correlation of change in body weight compared to the baseline clinical characteristics 1 week after starting tolvaptan. We also investigated the clinical characteristic changes between the results at baseline and post-treatment, calculating for the influence to clinical response and the safety and risk assessments.
Statistical analyses
Data were analyzed using the JMP 11.0.1 statistical software (SAS Institute Inc., Cary, NC, USA). All data are expressed as mean ± standard deviation. Continuous variables of responders and non-responders were compared by Mann-Whitney U-test and the Wilcoxon signed-rank test was used for paired data. Univariate and multivariate analyses with logistic regression models were used to calculate the odds ratios and the 95% confidence intervals to assess the correlation between the treatment factors and the response to tolvaptan. Correlations between changes in body weight and characteristics before or after drug treatment were determined using Pearson's r coefficient. Receiver-operating characteristic (ROC) curves were constructed to establish sensitivity-specificity relationships. Cut-off values that provided the best combinations of sensitivity and specificity were determined by ROC curve analyses. All differences with a P-value of less than 0.05 were considered significant. Statistical analysis was carried out by the Satt Corporation (Tokyo, Japan). Table 1 . The mean age was 65.7 ± 15.0 years (range, 22À90 years), the mean body weight was 61.0 ± 12.0 kg (range, 43.0À104.8 kg), and the mean body weight at the administration day of standard diuretic therapy was 57.5 ± 12.4 kg (range, 42.1À103.0 kg). The mean body weight at baseline was significantly higher than at the administration day of standard diuretic therapy (P < 0.0001). Twenty-six patients (60.4%) were male, and 13 patients (30.2%) had liver cancer. Twenty patients (46.5%) had liver cirrhosis not caused by hepatic viruses (alcoholic liver cirrhosis, n = 13; unknown or other causes, n = 7). The mean daily dose of furosemide was 48.8 ± 28.1 mg (range, 20À120 mg), and that of spironolactone was 48.4 ± 24.3 mg (range, 25À100 mg). The mean duration of preceding standard diuretic therapy was 21.4 ± 24.3 days (range, 7À92 days). The mean level of serum 
RESULTS
Patients and baseline characteristics
Clinical effects
After treatment with tolvaptan, a significant increase in the mean urine excretion volume from 1194.5 ± 668.9 mL pretreatment to 2344.4 ± 1384.4 mL post-treatment was observed (P < 0.0001, Fig. 1a ).
The decreases in body weight between the base line and the final dosing day were À2.47 ± 3.34 kg (P < 0.0001, Fig. 1b ). There were 20 (46.5%) responders to this drug.
Clinical characteristics of responder patients
Urinary sodium excretion was significantly higher in responders compared with non-responders (108.2 ± 70.5 vs 42.6 ± 36.7, P = 0.0003) ( Table 1) . The pre-treatment urinary volume excretion was higher in responders than that in non-responders (1462.8 ± 625.8 vs 960.9 ± 600.6, P = 0.0073). Urinary potassium was higher in responders compared with non-responders (26.9 ± 14.4 vs 16.1 ± 8.06, P = 0.0049). Baseline body weight was higher in responders compared with non-responders (66.1 ± 14.0 vs 56.5 ± 6.92, P = 0.0139). Renal function represented by 24-h Ccr was indistinguishable among responders and non-responders (61.2 ± 30.4 vs 47.6 ± 28.5, P = 0.1028). Liver function represented by Child-Pugh score was indistinguishable among responders and non-responders (10.3 ± 1.45 vs 10.5 ± 1.27, P = 0.6631). There were no significant differences in the age, body mass index, liver cancer, the doses of diuretics, platelets, serum albumin, serum BUN, serum creatinine, serum sodium, serum OSM, plasma BNP, plasma AVP, or urinary OSM between responders and non-responders.
Correlated clinical characteristics for response to tolvaptan
We evaluated the relation between body weight change and the baseline clinical characteristics on a logistic regression model (Table 2 ). Urinary volume, sodium, and potassium were correlated for the response to tolvaptan according to the univariate analysis of the pre-treatment. Multivariate analysis confirmed that urinary sodium levels were independent from the factors of the responders to this drug (P = 0.0114; hazard ratio, 0.9418; 95% confidence interval, 0.8768À0.9896). According to the multivariable analysis to baseline, body weight, urine volume, Figure 1 Mean changes in urine volume (a) and body weight (b) from baseline (BL) in liver cirrhosis patients with ascites treated with 7.5 mg/day tolvaptan. Data are expressed as mean ± standard deviation. Comparisons between each group and BL were carried out using the Wilcoxon signed-rank test (*P < 0.0001). 
Correlated factors to tolvaptan in liver cirrhosis
and urinary potassium were not correlated for the response to tolvaptan.
Change in clinical characteristics between baseline and post-treatment
In the laboratory data, plasma AVP was higher posttreatment compared with the baseline (2.31 ± 1.43 vs 3.85 ± 2.38, P < 0.0001) (Fig. 2) . In the urinary data, urinary sodium and potassium were higher posttreatment compared with the baseline (73.0 ± 64.4 vs 101.6 ± 68.7, P = 0.0021; 21.1 ± 12.9 vs 28.1 ± 22.9, P = 0.0186). Urinary OSM was lower post-treatment compared with the baseline (413.1 ± 142.0 vs 310.8 ± 94.9, P = 0.043). Renal function represented by 24-h Ccr was indistinguishable between the baseline and post-treatment (53.9 ± 30.7 vs 53.8 ± 37.1, P = 0.7047). There were no significant differences in platelets, serum albumin, serum bilirubin, serum creatinine, serum sodium, plasma BNP, plasma renin, or plasma aldosterone between the baseline and post-treatment.
Correlation between body weight change and post-treatment urinary sodium excretion
The correlation between body weight changes and baseline urine sodium was moderate (r = À0.5490, P = 0.0003). However, the correlation between body weight changes and post-treatment urine sodium was more prominent (r = À0.6940, P < 0.0001) (Fig. 3) . The correlation coefficient at post-treatment was higher than at pre-treatment in urinary sodium excretion. Body weight decreased in proportion to levels of urine sodium excretion. There were no correlations between the increase in urinary sodium and the dose of diuretics (P = 0.5406), the duration of the preceding diuretic therapy (P = 0.4251), or the baseline characteristics.
Receiver-operating characteristic curve analysis of body weight loss in liver cirrhosis patients
The respective cut-off points for body weight loss after treatment with tolvaptan were estimated using ROC curves for the baseline urine sodium (Fig. 4) . Using a cut-off for urine sodium excretion of 42.5 mEq/day, predicting body weight loss had a sensitivity of 78.1% and a specificity of 31.0%.
DISCUSSION
W E EVALUTATED THE correlation of treatmentcorrelated factors to response after treatment with tolvaptan in liver cirrhosis patients with ascites. In this retrospective cohort study, we showed that the calculation of the urine excretion sodium was useful for a prediction of the response to this drug. We also pointed out that the correlation of urinary sodium excretion was much stronger than urinary volume excretion. Tolvaptan is a non-peptide orally active V 2 receptor antagonist that competes with vasopressin for attachment to V 2 receptors at the renal collecting duct. 7, 8 Although the diuretic response to tolvaptan was considered to be dependent on primitive urine in the collecting tubules or on renal blood flow and glomerular filtration rate, [17] [18] [19] creatinine, BUN, and 24-h Ccr were not useful for the prediction of diuretic response to this drug in heart failure patients. That is because the efficacy of this drug may be weakened in patients with more severe tubulointerstitial damage than in patients with glomerular changes. 17, 18 Therefore, increased urine aquaporin-2 and delta-urinary OSM, which directly reflect an effect of V 2 receptor antagonist, was reported as a good predictor of diuretic response to tolvaptan in heart failure patients. 19 We consider that these predictors are useful for our study if the clinical effect was diuretic response. However, body weight changes as a clinical effect to this drug are expected to be different from the diuretic responses because an excessive fluid accumulation in liver cirrhosis is dependent upon sodium reabsorption more than water reabsorption. 20 The pathophysiology of ascites formation in liver cirrhosis is considered the reduced ability to excrete sodium and free water. 21 The trigger for fluid and sodium retention in liver cirrhosis is peripheral arterial vasodilation caused by portal hypertension. Consequently, leading to underfilling of circulatory volume, activation of the RAAS, the sympathetic nervous system, and antidiuretic hormone occur to restore the normal blood homeostasis. 22 For management of liver cirrhosis with ascites, one of the targets is a negative sodium balance in the body. Current guidelines recommend a restriction of sodium intake in liver cirrhosis patients with ascites, facilitating the elimination of ascites, and the excretion of fluid, that is, a diuretic therapy to achieve a negative sodium balance considering the low Figure 3 Relationships between mean change in body weight and pre-treatment 24-h mean urine sodium excretion (a), and post-treatment 24-h mean urine sodium excretion (b) in liver cirrhosis patients with ascites treated with 7.5 mg/day tolvaptan for 7 days, using Pearson's r coefficient. Figure 4 Decrease in body weight in liver cirrhosis patients with ascites treated with 7.5 mg/day tolvaptan for 7 days stratified by receiver-operating characteristic curves for pre-treatment urine sodium excretion. AUC, area under the curve. efficacy of salt restriction. 23 Diuretics block sodium reabsorption along the various nephron sites, increasing renal sodium excretion. If renal sodium excretion is insufficient after treatment with diuretics, it necessitates increasing the doses of the diuretics to as much as can be tolerated, up to the maximum recommended levels, and carefully monitoring the patient. 23 Thereby, conventional treatment is increasing renal sodium excretion, and then water excretion follows naturally. 24 Current guidelines do not recommend restriction of water intake other than for the treatment of dilutional hyponatremia (serum Na < 130 mEq/L). 24 New diuretic therapy with tolvaptan, which restricts water reabsorption, warrants discussion regarding the decrease in body weight for enrolled decompensated liver cirrhosis patients who showed insufficient responses to conventional diuretics. We offer two hypotheses for this response. The first could be that blocking water reabsorption may have a synergistic effect of diuretics blocking sodium reabsorption in severe liver cirrhosis patients. Although the current guidelines only recommend achievement of negative sodium balance, water retention owing to the high circulating plasma levels of antidiuretic hormone in the renal collecting duct in patients with severe liver cirrhosis is significant. Free water clearance in severe liver cirrhosis with ascites is lower than 1 mL/min, whereas that in healthy individuals approaches 10 mL/min; 25 therefore, there is a need to restrict water reabsorption in severe liver cirrhosis. We suspected that a new diuretic therapy blocking sodium and water reabsorption is more effective than the conventional therapy of only blocking sodium reabsorption in liver cirrhosis with ascites. 26 Furthermore, the progression of free water reabsorption with liver cirrhosis may reduce the effects of this drug. In our study, the non-responder group had higher urine OSM and lower urinary sodium excretion compared with the responder group. This result may mean the reabsorption of free water in the non-responder group is higher than in the responder group. 27 The second hypothesis is that tolvaptan may possibly increase urinary sodium excretion. We pointed out that urinary sodium and potassium were higher post-treatment compared with the baseline. Tolvaptan, a selective oral vasopressin V 2 receptor antagonist, may act on renal electrolytes including sodium excretion while promoting renal water reabsorption and decreasing excretion of free water. The fact of increasing urinary sodium excretion explains the reason that the correlation of post-treatment urinary sodium excretion was much stronger than that at the baseline for the response after administration. As the precise mechanisms were unknown, several previous reports showed a significant relationship between tolvaptan and the epithelial sodium channel (ENaC) in sodium excretion in urine. 28, 29 The ENaC activated by vasopressin increases sodium reabsorption along the distal nephron and contributes to the maintenance of the axial corticomedullary osmotic gradient necessary for maximal water reabsorption. 30 That is, tolvaptan may prevent sodium reabsorption by the ENaC activated along the distal nephron and consequently increase urinary sodium excretion. New diuretic therapy with tolvaptan may be an effective therapeutic approach in decompensated liver cirrhosis.
This study has several limitations. First, the study was carried out at a single center and was retrospective. Therefore, there were a limited number of patients and selection bias. Second, we estimated the urinary sodium excretion as a parameter to assess the efficacy of tolvaptan. However, the parameters that predict body weight changes before treatment with tolvaptan are insufficient. We require further detailed research of the predictors in combination with multiple factors, such as increased urine aquaporin-2 and delta-urinary OSM. 31 Third, it is not clear whether or not tolvaptan improves prognosis in the long term, although our results confirmed the effect of reducing body weight in liver cirrhosis patients. Finally, we reported increased urinary sodium excretion after treatment with tolvaptan in decompensated liver failure. However, the precise mechanisms were unknown, and we did not design a careful study of furosemide and spironolactone, which have high natriuretic responses. In future research, discontinuing furosemide treatment prior to tolvaptan treatment will make it possible to estimate the correlation between urinary sodium excretion and efficacy more accurately.
In conclusion, urinary sodium excretion may be well correlated with the response of tolvaptan in liver cirrhosis patients with ascites. Measurement of urinary sodium excretion levels may predict tolvaptan response.
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